CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

MoonLake Q3 R&D expenses rise 37% quarter over quarter to $68.9 million

By Public Technologies
  • MoonLake’s third-quarter 2026 R&D expenses rose 37% quarter-over-quarter to $68.9 million, while general and administrative expenses fell to $11 million.
  • Cash, cash equivalents and short-term marketable debt securities totaled $498.5 million at September 30, with cash runway expected through mid-2028.
  • A sonelokimab application for hidradenitis suppurativa was submitted to the FDA; a US launch is expected in H2 2027, if approved.
  • Sonelokimab 60 mg with induction met all Week 16 clinical endpoints in IZAR-1; initial IZAR-2 results are expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED1001301616) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk